Amylin | |
Deficiency | Type 1, type 2 diabetes |
Site of synthesis | Pancreatic beta cells |
Glucose-dependent stimulation of insulin secretion | No |
Reduction of gastric emptying | Yes |
Reduction of inappropriate glucagon secretion | Yes |
Weight loss | Yes |
Beta cell proliferation/regeneration | Unknown |
Therapies | Pramlintide (Symlin) |
Target population | Type 1 diabetes and insulin-treated type 2 diabetes |
Do you want to add Medilib to your home screen?